Health Canada clears Vivimind
This article was originally published in The Tan Sheet
Ovos Natural Health receives a Natural Health Product Number for its homotaurine amino acid supplement, allowing the Laval, Quebec, firm to sell Vivimind at retail in Canada. The issuance from Health Canada, announced Sept. 30, allows Ovos "to move forward with our search for a partner to commercialize Vivimind on a larger scale in Canada," where it previously was available only online, said Roberto Bellini, CEO of parent company Bellus Health. Ovos said it hoped to introduce the cognitive health product in the U.S. in 2010, but still has not received a reply from FDA on its citizen petition asking for permission to market homotaurine, a former investigational new drug candidate, as a new dietary ingredient (1"The Tan Sheet" Aug. 2, 2010)
You may also be interested in...
FDA says current dietary supplement regulations make clear that citizen petitions can be filed to request approval of ingredients that were studied in clinical trials and were part of unsuccessful investigational new drug applications
Biotech CEOs often express surprise when the FDA rejects their drugs. But collaborative interactions between regulators and drug sponsors count for little if the latter fail to adjust their clinical and regulatory efforts accordingly.
Special guest, Citeline's Annie Siu, discusses the recent ESMO meeting and Jiangsu Hengrui and BeiGene's PD-1 data for hepatocellular carcinoma in this latest episode of the Chinese-language China Biotech podcast.